Co-Managing Patients with Type 1 Diabetes and Cancer

Conor John Best, Sonali Thosani, Marjorie Ortiz, Celia Levesque, Sigi S. Varghese, Victor R Lavis

Research output: Contribution to journalReview article

Abstract

The life expectancy of people with type 1 diabetes is improving and now approaches that of those without diabetes. As this population ages, a growing number will be diagnosed with and treated for cancer. Cancer treatments can drastically affect insulin requirement and glycemic control through multiple mechanisms including high doses of glucocorticoids and targeted therapies that directly interfere with cellular pathways involved in the action of insulin. Patients with cancer frequently also have alterations in gastrointestinal motility or appetite and require supplemental enteral or parenteral nutrition. Few studies have evaluated these patients directly, but data on patients with and without diabetes suggest that glycemic control may play a larger role in cancer outcomes than is often recognized. Collaboration between the treating oncologist and diabetologist allows people with diabetes to receive the most effective therapies for their cancers without undue risk of hypoglycemia or adverse outcomes due to hyperglycemia.

Original languageEnglish (US)
Article number73
JournalCurrent Diabetes Reports
Volume16
Issue number8
DOIs
StatePublished - Aug 1 2016

Fingerprint

Type 1 Diabetes Mellitus
Neoplasms
Insulin
Gastrointestinal Motility
Parenteral Nutrition
Enteral Nutrition
Appetite
Life Expectancy
Hypoglycemia
Hyperglycemia
Glucocorticoids
Therapeutics
Population

Keywords

  • Cancer
  • Chemotherapy
  • Glucocorticoids
  • Hyperalimentation
  • Targeted cancer therapy
  • Type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Co-Managing Patients with Type 1 Diabetes and Cancer. / Best, Conor John; Thosani, Sonali; Ortiz, Marjorie; Levesque, Celia; Varghese, Sigi S.; Lavis, Victor R.

In: Current Diabetes Reports, Vol. 16, No. 8, 73, 01.08.2016.

Research output: Contribution to journalReview article

Best, Conor John ; Thosani, Sonali ; Ortiz, Marjorie ; Levesque, Celia ; Varghese, Sigi S. ; Lavis, Victor R. / Co-Managing Patients with Type 1 Diabetes and Cancer. In: Current Diabetes Reports. 2016 ; Vol. 16, No. 8.
@article{0358fe4e694b4c24aeedc1fb49380dc1,
title = "Co-Managing Patients with Type 1 Diabetes and Cancer",
abstract = "The life expectancy of people with type 1 diabetes is improving and now approaches that of those without diabetes. As this population ages, a growing number will be diagnosed with and treated for cancer. Cancer treatments can drastically affect insulin requirement and glycemic control through multiple mechanisms including high doses of glucocorticoids and targeted therapies that directly interfere with cellular pathways involved in the action of insulin. Patients with cancer frequently also have alterations in gastrointestinal motility or appetite and require supplemental enteral or parenteral nutrition. Few studies have evaluated these patients directly, but data on patients with and without diabetes suggest that glycemic control may play a larger role in cancer outcomes than is often recognized. Collaboration between the treating oncologist and diabetologist allows people with diabetes to receive the most effective therapies for their cancers without undue risk of hypoglycemia or adverse outcomes due to hyperglycemia.",
keywords = "Cancer, Chemotherapy, Glucocorticoids, Hyperalimentation, Targeted cancer therapy, Type 1 diabetes",
author = "Best, {Conor John} and Sonali Thosani and Marjorie Ortiz and Celia Levesque and Varghese, {Sigi S.} and Lavis, {Victor R}",
year = "2016",
month = "8",
day = "1",
doi = "10.1007/s11892-016-0766-y",
language = "English (US)",
volume = "16",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "8",

}

TY - JOUR

T1 - Co-Managing Patients with Type 1 Diabetes and Cancer

AU - Best, Conor John

AU - Thosani, Sonali

AU - Ortiz, Marjorie

AU - Levesque, Celia

AU - Varghese, Sigi S.

AU - Lavis, Victor R

PY - 2016/8/1

Y1 - 2016/8/1

N2 - The life expectancy of people with type 1 diabetes is improving and now approaches that of those without diabetes. As this population ages, a growing number will be diagnosed with and treated for cancer. Cancer treatments can drastically affect insulin requirement and glycemic control through multiple mechanisms including high doses of glucocorticoids and targeted therapies that directly interfere with cellular pathways involved in the action of insulin. Patients with cancer frequently also have alterations in gastrointestinal motility or appetite and require supplemental enteral or parenteral nutrition. Few studies have evaluated these patients directly, but data on patients with and without diabetes suggest that glycemic control may play a larger role in cancer outcomes than is often recognized. Collaboration between the treating oncologist and diabetologist allows people with diabetes to receive the most effective therapies for their cancers without undue risk of hypoglycemia or adverse outcomes due to hyperglycemia.

AB - The life expectancy of people with type 1 diabetes is improving and now approaches that of those without diabetes. As this population ages, a growing number will be diagnosed with and treated for cancer. Cancer treatments can drastically affect insulin requirement and glycemic control through multiple mechanisms including high doses of glucocorticoids and targeted therapies that directly interfere with cellular pathways involved in the action of insulin. Patients with cancer frequently also have alterations in gastrointestinal motility or appetite and require supplemental enteral or parenteral nutrition. Few studies have evaluated these patients directly, but data on patients with and without diabetes suggest that glycemic control may play a larger role in cancer outcomes than is often recognized. Collaboration between the treating oncologist and diabetologist allows people with diabetes to receive the most effective therapies for their cancers without undue risk of hypoglycemia or adverse outcomes due to hyperglycemia.

KW - Cancer

KW - Chemotherapy

KW - Glucocorticoids

KW - Hyperalimentation

KW - Targeted cancer therapy

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84976330480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976330480&partnerID=8YFLogxK

U2 - 10.1007/s11892-016-0766-y

DO - 10.1007/s11892-016-0766-y

M3 - Review article

C2 - 27319323

AN - SCOPUS:84976330480

VL - 16

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 8

M1 - 73

ER -